2U3:FRA
Alcon AG
၅၇.၆၈ €
arrow_upward
+၁.၃၄%(+၀.၇၆) 1D
အောက် ၁၂, GMT+၂ ၁၅:၃၃:၀၈ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2U3...
Open
၅၆.၆၈ €
High
၅၇.၆၈ €
Low
၅၆.၆၈ €
Mkt. cap
ဋေ ၂.၆၇ ထ
Avg. vol.
၁၃၀.၀၀
Volume
၁၀၄.၀၀
52-wk high
၇၃.၉၆ €
52-wk low
၅၁.၇၈ €
No. of employees
၂ သောင်း
Open
၅၆.၆၈ €
High
၅၇.၆၈ €
Low
၅၆.၆၈ €
Mkt. cap
ဋေ ၂.၆၇ ထ
Avg. vol.
၁၃၀.၀၀
Volume
၁၀၄.၀၀
52-wk high
၇၃.၉၆ €
52-wk low
၅၁.၇၈ €
No. of employees
၂ သောင်း
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၅၇ မိနစ်
Alcon launches Systane PRO in Canada: stock after-hours at EUR 57.42
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၉ နာရီ
Alcon posts 256-patient data while Alcon stock sits 21.38 percent below its high
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ ရက်
Alcon highlights AAO innovation as Alcon stock sits at EUR 57.28
Simply Wall Street
·
ပြီးခဲ့သည့် ၂ ရက်
What Alcon Shares Launch Of New Dry Eye Drops In Canada Means For Shareholders
Profile
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
About Alcon AG
CEODavid J. Endicott
Employees၂.၅ သောင်း
Founded၁၉၄၅
Headquartersဂျနီဗာမြို့, Geneva, ဆွစ်ဇာလန်
Sector-
Websitealcon.com